The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XENE | -16.38% | +248.68% | +28.34% | +264% |
| S&P | +12.65% | +91.73% | +13.89% | +233% |
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
These top performers have what it takes to keep providing outsized gains for patient investors.
Despite the big run-up yesterday, there could be enough fuel to push this biotech stock even higher.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.64M | 4.2% |
| Gross Margin | 91.21% | 0.0% |
| Market Cap | $3.10B | 3.8% |
| Market Cap / Employee | $9.47M | 0.0% |
| Employees | 327 | 26.3% |
| Net Income | -$90.90M | -44.8% |
| EBITDA | -$95.70M | -31.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $104.51M | 19.3% |
| Accounts Receivable | $0.81M | -13.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.83M | -18.7% |
| Short Term Debt | $1.50M | 7.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -42.44% | -14.1% |
| Return On Invested Capital | -19.60% | 1.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$72.75M | -40.5% |
| Operating Free Cash Flow | -$72.46M | -41.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.72 | 3.40 | 3.41 | 4.87 | 30.27% |
| Price to Sales | 352.00 | 329.50 | 424.24 | - | |
| Price to Tangible Book Value | 3.72 | 3.40 | 3.41 | 4.87 | 30.27% |
| Enterprise Value to EBITDA | -31.95 | -29.12 | -21.29 | -28.51 | -14.14% |
| Return on Equity | -27.8% | -31.6% | -37.6% | -45.1% | 51.71% |
| Total Debt | $9.02M | $8.68M | $8.72M | $8.33M | -14.91% |
No podcast episodes available.
XENE earnings call for the period ending September 30, 2020.
XENE earnings call for the period ending June 30, 2020.
XENE earnings call for the period ending March 31, 2020.
XENE earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
